# KRASCENDO 3: HCP commentary report

> 10 verified statements (4 from clinicians verified by NPI or staff page) from 6 commentary sources · 3 findings · updated Nov 1, 2026

## Report

- Trial: A Phase III, Randomized, Open-label Study Evaluating the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Patients With Resected Stage II-III KRAS G12C-Positive Non-small Cell Lung Cancer
- NCT ID: NCT07541170
- Registry: https://clinicaltrials.gov/study/NCT07541170
- Sponsor: Hoffmann-La Roche
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: divarasib
- Indication: resected stage II-III KRAS G12C-positive NSCLC
- Version: v1.0.0, edition 1
- Accepted: 2026-11-01
- Last checked: 2026-11-01
- Release hash: dc39c00b5a8657974c595b66e62c4b8ddf958677a13946fb83cecc9a2c6d6410

## Counts

- HCP commentary sources screened: 14
- Sources cited by verified statements: 7
- Verified statements: 10
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 4
- Findings: 3
- Named people in screened sources (unnamed speakers and accounts not counted): 4
- Voices cited: 4
- Cited voices identity-verified: 4
- Organisational or shared accounts (not counted as people): 2

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

KRASCENDO 3 tests whether divarasib improves disease-free survival after resection of stage II–III KRAS G12C-positive non-small cell lung cancer; discussion centers on a favorable NAUTIKA1 nodal observation and the threshold for standard-care endorsement. The report cites three medical oncologists. Further questions concern NAUTIKA1’s role in additional evaluation and durable patient benefit from early-stage KRAS G12C inhibition. What postoperative evidence would justify moving from a feasibility signal to routine care?

## Open Medical Affairs question

What postoperative evidence would justify moving from a feasibility signal to routine-care adoption?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. A favorable nodal observation does not amount to standard-care endorsement
- F2. NAUTIKA1 is read as a feasibility rationale for further evaluation
- F3. Early-stage interest leaves durable patient benefit as an open question

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 2 | 1 | 1 | 1 | none recorded | 2 |
| F2 | 7 | 5 | 5 | 4 | recorded | 4 |
| F3 | 2 | 2 | 2 | 2 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 1 post or article | yes |
| F2 | 4 | 0 | 0 | 0 | 3 | 7 | 1 | 4 posts and articles, 1 registry | yes |
| F3 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 2 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Disease-free Survival (DFS), as Determined by the Investigator: no finding draws on it directly
- Secondary endpoint: Overall Survival (OS): no finding draws on it directly
- Secondary endpoint: DFS Rates at 2 and 3 Years, as Assessed by the Investigator: no finding draws on it directly
- Secondary endpoint: Number of Participants With Adverse Events (AEs): no finding draws on it directly
- Population and setting: F3 (1 shared claims)
- The comparison: no finding draws on it directly
- Safety and tolerability: F2 (2 shared claims)
- Design and conduct: no finding draws on it directly

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. NAUTIKA1 is read as a feasibility rationale for further evaluation

An organizational X thread prompts a methodological question about how neoadjuvant NAUTIKA1 evidence should inform postoperative evaluation in KRASCENDO 3.

The thread summarizes publicly released abstract material, not presentation slides.

Source: X thread, 2026-09-03.

### F3. Early-stage interest leaves durable patient benefit as an open question

A medical oncologist’s LinkedIn post provides context for asking how to assess the scope of durable-benefit commentary.

Source: LinkedIn post, 2026-10-19.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 3 | Titles free |
| Detailed analysis | 4 sections | Paid |
| Verified statements with short source quotes and links | 10 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 7 | Counts free |
| Speaker attribution for cited voices | 4 | Paid |

## Trial aspects

5 discussed · 6 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Disease-free Survival (DFS), as Determined by the Investigator | no commentary found | 0 | 0 |
| Secondary endpoint: Overall Survival (OS) | no commentary found | 0 | 0 |
| Secondary endpoint: DFS Rates at 2 and 3 Years, as Assessed by the Investigator | no commentary found | 0 | 0 |
| Secondary endpoint: Number of Participants With Adverse Events (AEs) | no commentary found | 0 | 0 |
| Population and setting | discussed | 1 | 1 |
| The comparison | no commentary found | 0 | 0 |
| Safety and tolerability | discussed | 2 | 2 |
| Design and conduct | no commentary found | 0 | 0 |
| NAUTIKA1 and the threshold for standard care | discussed | 2 | 1 |
| NAUTIKA1 feasibility as a rationale for postoperative evaluation | discussed | 4 | 3 |
| Early-stage interest and the durable-benefit question | discussed | 2 | 2 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 11 | 5 |
| LinkedIn posts | 1 | 1 |
| Bluesky threads | 1 | 0 |
| YouTube | 1 | 0 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2026-05-10 to 2026-10-31
- Cited window: 2026-05-10 to 2026-10-19
- Retrieved: 2026-11-01

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase III, Randomized, Open-label Study Evaluating the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Patients With Resected Stage II-III KRAS G12C-Positive Non-small Cell Lung Cancer
- Registry: NCT07541170 (https://clinicaltrials.gov/study/NCT07541170)
- Study IDs: BO45885 · 2025-524263-21-00
- Sponsor: Hoffmann-La Roche
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 400 (estimated)
- Start: 2026-10-06 (actual)
- Primary completion: 2032-01-31 (estimated)
- Primary endpoint: Disease-free Survival (DFS), as Determined by the Investigator (From randomization to disease recurrence or death from any cause (Up to approximately 5 years))
- Intervention: Divarasib (drug)
- Intervention: Pembrolizumab (drug)
- Intervention: Nivolumab (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 11 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The views come from the sources reviewed for this edition, not a representative sample of HCP opinion. Multiple posts discuss the same NAUTIKA1 cohort and should not be counted as independent clinical evidence.
- Coverage concentrated on the trial identifier and known names. Unnamed references and different transcriptions may be missing, and several potentially relevant passages have not been fully assessed.
- No publication reporting NCT07541170 was identified, no separate protocol document was listed in the registry, and no exact divarasib regulatory label was found. These absences do not establish publication or regulatory status.
- The substantive activity, surgical-feasibility and tolerability observations concern a small neoadjuvant phase II NAUTIKA1 cohort, not randomized postoperative KRASCENDO3 outcomes.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- A speaker's statement relays another party's early-stage perspective; it should not be treated as his own regimen-specific recommendation.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-11-01: current edition

Last checked for new commentary 2026-11-01. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (10 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (4 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/krascendo-3-nct07541170
- Agents: POST https://www.erudio.com/api/orders with {"report": "krascendo-3-nct07541170", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=krascendo-3-07541170

## Cite

Erudio Health. KRASCENDO 3 (NCT07541170): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 1, 2026. https://www.erudio.com/reports/krascendo-3-nct07541170

## Machine access

- JSON: https://www.erudio.com/reports/krascendo-3-nct07541170.json
- Markdown: https://www.erudio.com/reports/krascendo-3-nct07541170.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "krascendo-3-07541170"}`